iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/21248225
Mutant proteins as cancer-specific biomarkers - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 8;108(6):2444-9.
doi: 10.1073/pnas.1019203108. Epub 2011 Jan 19.

Mutant proteins as cancer-specific biomarkers

Qing Wang  1 , Raghothama Chaerkady, Jian Wu, Hee Jung Hwang, Nick Papadopoulos, Levy Kopelovich, Anirban Maitra, Hanno Matthaei, James R Eshleman, Ralph H Hruban, Kenneth W Kinzler, Akhilesh Pandey, Bert Vogelstein
Affiliations

Mutant proteins as cancer-specific biomarkers

Qing Wang et al. Proc Natl Acad Sci U S A. .

Abstract

Cancer biomarkers are currently the subject of intense research because of their potential utility for diagnosis, prognosis, and targeted therapy. In theory, the gene products resulting from somatic mutations are the ultimate protein biomarkers, being not simply associated with tumors but actually responsible for tumorigenesis. We show here that the altered protein products resulting from somatic mutations can be identified directly and quantified by mass spectrometry. The peptides expressed from normal and mutant alleles were detected by selected reaction monitoring (SRM) of their product ions using a triple-quadrupole mass spectrometer. As a prototypical example of this approach, we demonstrated that it is possible to quantify the number and fraction of mutant Ras protein present in cancer cell lines. There were an average of 1.3 million molecules of Ras protein per cell, and the ratio of mutant to normal Ras proteins ranged from 0.49 to 5.6. Similarly, we found that mutant Ras proteins could be detected and quantified in clinical specimens such as colorectal and pancreatic tumor tissues as well as in premalignant pancreatic cyst fluids. In addition to answering basic questions about the relative levels of genetically abnormal proteins in tumors, this approach could prove useful for diagnostic applications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Schematic of the approach.
Fig. 2.
Fig. 2.
IP of Ras proteins. An antibody directed against a common epitope of all three forms of mutant and WT forms of Ras (K-Ras, N-Ras, and H-Ras) was used to immunoprecipitate the indicated amounts of protein in SW480 cell lysates. Western blots were performed using an HRP-conjugated monoclonal antibody to K-Ras. Ten nanograms of recombinant K-Ras protein were loaded on the right-most lane of each gel for comparison purposes. The “input lysate” and “lysate after IP” lanes contained 4% of the proteins used for IP; all the eluted protein and protein remaining on beads were loaded into the corresponding lanes.
Fig. 3.
Fig. 3.
Extracted ion chromatograms of 13C/15N-labeled synthetic peptides. The retention times of the indicated peptides are shown above the peaks in A–C, and the insets at the right of each panel represent an expanded view. Asterisks indicate the heavy isotope (13C6/15N2)-labeled lysine. D–F illustrate the relationship between the amount of peptide injected into the mass spectrometer and the integrated intensity of the transitions. The b and y peaks indicate the detected intensities of b ions and y ions (as designated in Table S1).
Fig. 4.
Fig. 4.
SRM of endogenous proteins from SW480 cells. (A and B) Extracted ion chromatograms of transitions from (A) exogenously added heavy isotope-labeled WT peptide and (B) corresponding endogenous WT peptide, illustrating the identical retention times. (C and D) Extracted ion chromatograms of the (C) exogenous and (D) endogenous mutant peptides. In each panel, the inset at the right represents an expanded view of the major peaks. Asterisks indicate the heavy isotope (13C6/15N2)-labeled lysine.
Fig. 5.
Fig. 5.
SRM of endogenous proteins from a colorectal tumor obtained at surgery. (A) Integrated intensities of the exogenously added mutant peptide and the endogenous mutant peptide from the tumor, as indicated. The integrated intensities correspond to the sum of the peak areas of the transitions described in Table S1, which are shown in B for the endogenous peptide. The asterisk indicates the heavy isotope (13C6/15N2) labeled lysine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wood LD, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–1113. - PubMed
    1. Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806. - PMC - PubMed
    1. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. - PMC - PubMed
    1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724. - PMC - PubMed
    1. Bignell GR, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463:893–898. - PMC - PubMed

Publication types